MARKET

CELG

Celgene
CELG
NASDAQ
Delisted
P/E
P/S
P/B
MARKET CAP
19.84
4.606
6.37
77,001,936,000.00
Bristol Myers CEO on second quarter, infrastructure
Bloomberg · 07/28 17:30
Bristol-Myers CEO on Delta Variant, Return of Office Workforce
Bloomberg · 07/28 17:18
Biogen Decision Clarifies FDA Alzheimer’s Standard, Bristol Says
Bloomberg · 07/28 13:44
Bristol Myers Strikes $1.6 Billion Pact for New Cancer Drug
Bristol Myers Squibb Co. has agreed to pay Agenus Inc. as much as $1.56 billion for the rights to a new kind of experimental drug that uses the body’s immune system to combat cancer.
Bloomberg · 05/18 13:12
UPDATE 1-FDA approves Bristol-Myers' gene therapy for white blood cell cancer
reuters.com · 02/05 21:17
Bristol Myers 4th quarter profit tops Street view on strong sales from Celgene drugs
reuters.com · 02/04 11:59
Jounce Therapeutics: An Undervalued Biotech Flush With Big Pharma Cash
Jounce therapeutics is a differentiated player in the hot immuno-oncology sector.JNCE stock has not been fairly priced after its newly struck partnership with Gilead Sciences, making it a compelling buy for the short term.JNCE's drug discovery engine continues to impress, potentially making it an equally compelling pick for the longer term.
Seekingalpha · 09/11/2020 18:06
Biotech IPO Nkarta triples in debut
Seeking Alpha - Article · 07/10/2020 16:45
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CELG. Analyze the recent business situations of Celgene through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 18 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CELG stock price target is 104.00 with a high estimate of 116.00 and a low estimate of 86.00.
EPS
Institutional Holdings
Institutions: 1.39K
Institutional Holdings: 536.66M
% Owned: 75.44%
Shares Outstanding: 711.40M
TypeInstitutionsShares
Increased
328
54.08M
New
74
2.28M
Decreased
607
50.75M
Sold Out
163
22.98M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.40%
Pharmaceuticals & Medical Research
-0.10%
Key Executives
Chairman/Chief Executive Officer/Director
Mark Alles
Chief Financial Officer/Executive Vice President
David Elkins
Corporate Executive
Nadim Ahmed
Corporate Executive
Terrie Curran
Corporate Executive
Alise Reicin
Corporate Executive
Rupert Vessey
Executive Vice President/General Counsel
Jonathan Biller
Executive Vice President
Peter Kellogg
Lead Director
Michael Casey
Director
Hans Bishop
Independent Director
Richard Barker
Director
Patricia Hall
Independent Director
Michael Bonney
Independent Director
Carrie Cox
Independent Director
Michael Friedman
Independent Director
Julia Haller
Independent Director
Patricia Hemingway Hall
Independent Director
James Loughlin
Independent Director
Ernest Mario
Independent Director
John Weiland
No Data

Webull offers kinds of Celgene stock information, including NASDAQ:CELG real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CELG stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CELG stock methods without spending real money on the virtual paper trading platform.